Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2014 3
2015 4
2016 3
2017 3
2018 2
2019 3
2020 1
2021 4
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.
Iinuma K, Yamada T, Kameyama K, Taniguchi T, Kawada K, Ishida T, Nagai S, Enomoto T, Ueda S, Takagi K, Kawase M, Takeuchi S, Kawase K, Kato D, Takai M, Nakane K, Koie T. Iinuma K, et al. Among authors: kameyama k. Cancers (Basel). 2023 Feb 2;15(3):947. doi: 10.3390/cancers15030947. Cancers (Basel). 2023. PMID: 36765903 Free PMC article.
Exosomes expressing carbonic anhydrase 9 promote angiogenesis.
Horie K, Kawakami K, Fujita Y, Sugaya M, Kameyama K, Mizutani K, Deguchi T, Ito M. Horie K, et al. Among authors: kameyama k. Biochem Biophys Res Commun. 2017 Oct 21;492(3):356-361. doi: 10.1016/j.bbrc.2017.08.107. Epub 2017 Aug 26. Biochem Biophys Res Commun. 2017. PMID: 28851650
Isolation of prostate cancer-related exosomes.
Mizutani K, Terazawa R, Kameyama K, Kato T, Horie K, Tsuchiya T, Seike K, Ehara H, Fujita Y, Kawakami K, Ito M, Deguchi T. Mizutani K, et al. Among authors: kameyama k. Anticancer Res. 2014 Jul;34(7):3419-23. Anticancer Res. 2014. PMID: 24982349
Urinary exosome as a potential biomarker for urinary tract infection.
Mizutani K, Kawakami K, Horie K, Fujita Y, Kameyama K, Kato T, Nakane K, Tsuchiya T, Yasuda M, Masunaga K, Kasuya Y, Masuda Y, Deguchi T, Koie T, Ito M. Mizutani K, et al. Among authors: kameyama k. Cell Microbiol. 2019 Jul;21(7):e13020. doi: 10.1111/cmi.13020. Epub 2019 Mar 7. Cell Microbiol. 2019. PMID: 30817089
[A Case of Metastasis of Gastric Cancer to the Bladder].
Kameyama K, Toyota S, Kamei S, Yokoi S, Ishihara S, Deguchi T, Sugiyama S, Yamada T. Kameyama K, et al. Hinyokika Kiyo. 2021 Nov;67(11):497-500. doi: 10.14989/ActaUrolJap_67_11_497. Hinyokika Kiyo. 2021. PMID: 34856789 Free article. Japanese.
Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential VHL Mutations Underlie Multifocal ccRCC.
Mizutani K, Yokoi S, Sawada S, Sakamoto I, Kameyama K, Kamei S, Hirade K, Sugiyama S, Matsunaga K, Yamada T, Kato Y, Nishihara H, Ishihara S, Deguchi T. Mizutani K, et al. Among authors: kameyama k. Cancer Genomics Proteomics. 2022 Nov-Dec;19(6):740-746. doi: 10.21873/cgp.20356. Cancer Genomics Proteomics. 2022. PMID: 36316043 Free PMC article.
Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer.
Kawase M, Takagi K, Kawada K, Ishida T, Tomioka M, Enomoto T, Fujimoto S, Taniguchi T, Ito H, Kameyama K, Yamada T, Kawase K, Kato D, Takai M, Iinuma K, Nakane K, Koie T. Kawase M, et al. Among authors: kameyama k. Curr Oncol. 2022 Aug 1;29(8):5466-5474. doi: 10.3390/curroncol29080432. Curr Oncol. 2022. PMID: 36005170 Free PMC article.
Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.
Iinuma K, Tomioka-Inagawa R, Kameyama K, Taniguchi T, Kawada K, Ishida T, Nagai S, Enomoto T, Ueda S, Kawase M, Takeuchi S, Kawase K, Kato D, Takai M, Nakane K, Koie T. Iinuma K, et al. Among authors: kameyama k. Biomedicines. 2022 Dec 7;10(12):3172. doi: 10.3390/biomedicines10123172. Biomedicines. 2022. PMID: 36551927 Free PMC article.
Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.
Iinuma K, Kameyama K, Taniguchi T, Kawada K, Ishida T, Takagi K, Nagai S, Enomoto T, Tomioka M, Kawase M, Takeuchi S, Kato D, Takai M, Nakane K, Koie T. Iinuma K, et al. Among authors: kameyama k. Cancers (Basel). 2022 Sep 21;14(19):4579. doi: 10.3390/cancers14194579. Cancers (Basel). 2022. PMID: 36230501 Free PMC article.
30 results